SIGNIA Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
Acute respiratory tract infections (ARTI) represent the main cause of acute diseases worldwide and remain the number one cause of deaths in newborns and young children (nearly 2 million deaths/year). These respiratory pathogens represent a major public health issue and have a large socio-economic impact. Up to now, very few efficient vaccines or antiviral candidate treatments have been reported in the medical literature to widely fight against these respiratory pathogens, with the exception of those available against influenza viruses. In an effort to treat these various ARTIs, consumers spend $2-3 billion each year, yet new efficient antiviral strategies, less prone to the emergence of resistance, are necessary.
Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept already established for several FDA-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications. Ongoing programs are currently conducted by Signia Therapeutics and dedicated to the selection and validation of new broad-spectrum antiviral compounds against human respiratory syncytial virus, human metapneumovirus and human coronaviruses.
Signia Therapeutics is well positioned with an ongoing clinical trial (FLUNEXT) for the evaluation of one very promising antiviral candidate in 300 Flu patients, with final results expected in 2019-2020. This clinical trial is financed by the French Health Ministry and is directed by Julien Poissy (CHRU Lille) and Manuel Rosa-Calatrava. Ongoing programs are currently conducted by Signia Therapeutics and dedicated to the identification and validation of broad-spectrum antiviral compounds against Flu, RSV, hMPV and human Coronaviruses such as MERs-CoV.
Signia Therapeutics has obtained full international rights for three patents comprising repurposed marketed drugs as new antivirals against influenza viruses and the Middle East Respiratory Syndrome-related Coronavirus (MERS-CoV) (WO2016146836; PCT/EP2017/058009; PCT/FR2017/052889). These new antivirals were identified and validated through the company’s proprietary discovery platform and are now part of the Company’s pipeline and available for partnerships and licensing discussions.
With the advancement of its proprietary know-how, patented technology and the constitution of its own database, Signia Therapeutics will be able to present its technology and products to pharmaceutical and specialty pharma companies. The proprietary platform and database will bring partnership and revenue opportunities. This activity will also position Signia Therapeutics for future partnerships for their internally developed products with a focus on the Phase II product in the wide influenza market.
Mentions légales
Signia Therapeutics,
Société par Actions Simplifiée au capital de 15.000 euros
Siège social : L’Atrium – 43 boulevard du 11 novembre 1918
69100 Villeurbanne